The Medicare GLP-1 Eligibility Checklist: How to Qualify for $50/Month Weight Loss Medications Under Current Rules

For years, Medicare beneficiaries were specifically excluded from drug coverage for obesity and weight loss. That barrier has now cracked open. In 2026, Medicare beneficiaries can access GLP-1 receptor agonist medications—including Wegovy (semaglutide) and Zepbound (tirzepatide)—through specific access programs at dramatically reduced costs, with some pathways offering as low as $50 per month.

The rules are complicated, and access isn’t universal. This guide provides a plain-language eligibility checklist, explains the current access pathways, and tells you exactly what to ask your doctor and insurance plan to find out if you qualify.

Important Note: GLP-1 access for Medicare beneficiaries is a rapidly evolving area. The $50/month access point referenced in this article applies to specific programs, including TrumpRx direct pharmacy portals and select Medicare Advantage plan coverage pathways. Standard Medicare Part D coverage for weight-loss-only GLP-1 use remains restricted. This article reflects the state of available programs as of May 2026 — verify current eligibility with your plan or prescriber before taking action.

In This Article

1. What Are GLP-1 Medications and Why Do Seniors Want Them?
2. Medicare’s History With Weight Loss Drugs
3. Current Medicare Access Pathways in 2026
4. The GLP-1 Eligibility Checklist
5. How to Apply: Step-by-Step
6. What You’ll Pay: Cost Comparison by Pathway
7. What Seniors Should Know About GLP-1 Side Effects
8. Frequently Asked Questions

What Are GLP-1 Medications and Why Do Seniors Want Them?

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that were originally developed to treat Type 2 diabetes. Researchers discovered they also produce significant weight loss by slowing gastric emptying, reducing appetite, and altering food cravings at the neurological level.

The two most prominent weight-loss-specific GLP-1 medications are:

For adults over 60, these medications have shown particular relevance beyond weight loss: Wegovy received FDA approval for cardiovascular risk reduction in 2024, making it a Medicare-coverable drug in that context regardless of weight-loss goals.

Medicare’s History With Weight Loss Drugs: Why This Is a Big Deal

For most of Medicare’s existence, federal law explicitly prohibited Part D plans from covering drugs used for “weight loss, weight gain, or anorexia.” This exclusion applied even when obesity was clinically documented and contributing to other covered conditions.

That began to change with two developments:

1. Cardiovascular approval: When the FDA approved Wegovy for reducing cardiovascular events in patients with existing heart disease, Medicare could cover it under the heart disease benefit — not the weight loss exclusion.
2. TrumpRx program and direct-pricing portals: Executive-level programs established direct pricing pathways through preferred pharmacy portals, allowing qualifying Medicare beneficiaries to access GLP-1 medications at fixed low monthly costs outside the traditional Part D claim structure.

The result is a patchwork of overlapping coverage rules. Navigating them requires knowing exactly which pathway you qualify for.

Current Medicare Access Pathways for GLP-1 Drugs in 2026

Pathway 1: Cardiovascular Disease Coverage (Part D)

If you have a documented history of cardiovascular disease (heart attack, stroke, or established atherosclerotic cardiovascular disease), Wegovy is coverable by Medicare Part D under its cardiovascular risk indication. This is the most mainstream Medicare coverage pathway. Coverage is plan-dependent — your Part D or MA-PD plan must include semaglutide on its formulary.

Pathway 2: Type 2 Diabetes Coverage (Part D)

Ozempic and Mounjaro are FDA-approved for Type 2 diabetes management. Medicare Part D plans have covered these medications for diabetes for several years. If your primary indication is diabetes management and weight loss is a secondary benefit, this is the clearest coverage pathway.

Pathway 3: TrumpRx Direct-Access Portal

The TrumpRx program established direct-access portals allowing qualifying Medicare beneficiaries to obtain GLP-1 medications at a fixed cost—reported at approximately $50 per month—through preferred pharmacy partners. This pathway has specific BMI and health history eligibility requirements and operates differently from standard Part D claims. Availability and terms may vary; verify directly through the official portal.

Pathway 4: Medicare Advantage Plan Supplemental Coverage

Some Medicare Advantage plans have begun offering GLP-1 weight management coverage as a supplemental benefit, particularly for enrollees with documented obesity plus comorbidities (such as diabetes, hypertension, or sleep apnea). This varies significantly by plan and geography. Check your plan’s Evidence of Coverage (EOC) document or call member services.

Pathway 5: Pilot Programs and Innovation Models

CMS has established pilot frameworks testing expanded GLP-1 coverage for obesity as a standalone condition. Enrollment windows and geographic availability for these pilot programs are limited. Watch for CMS announcements regarding expanded enrollment.

The Medicare GLP-1 Eligibility Checklist

Use this checklist to determine which pathway(s) you may qualify for. Check every item that applies to your situation:

Cardiovascular Disease Pathway (Wegovy via Part D)

• ☐ You are enrolled in Medicare Part D or a Medicare Advantage plan with drug coverage (MA-PD)
• ☐ You have a documented diagnosis of cardiovascular disease, including prior heart attack (MI), prior stroke or TIA, or established atherosclerotic cardiovascular disease (ASCVD)
• ☐ Your doctor is willing to prescribe Wegovy (semaglutide 2.4mg) specifically for cardiovascular risk reduction
• ☐ Your Part D plan’s formulary includes semaglutide at an accessible cost-sharing tier

Type 2 Diabetes Pathway (Ozempic or Mounjaro via Part D)

• ☐ You have a documented Type 2 diabetes diagnosis
• ☐ You are enrolled in Medicare Part D or MA-PD
• ☐ Your current diabetes management protocol, as determined by your prescriber, warrants a GLP-1 receptor agonist
• ☐ Your plan’s formulary includes your preferred GLP-1 at a manageable cost-sharing tier

TrumpRx / Direct-Access $50 Program

• ☐ You are enrolled in Medicare
• ☐ Your BMI is 30 or above (or 27+ with at least one weight-related health condition)
• ☐ You have a documented weight-related comorbidity (e.g., high blood pressure, high cholesterol, Type 2 diabetes, sleep apnea, cardiovascular disease)
• ☐ You have received a prescription from a licensed provider
• ☐ You have verified current program availability and enrollment status through the official TrumpRx or designated portal

Medicare Advantage Supplemental Coverage

• ☐ You are enrolled in a Medicare Advantage (Part C) plan
• ☐ Your plan specifically lists GLP-1 medications for weight management in its Evidence of Coverage document
• ☐ You meet your plan’s specific eligibility criteria (check plan documents—these vary widely)

Critical Step: Before scheduling a GLP-1 prescription visit, call your plan’s pharmacy benefits line and ask, “Is [drug name] on your formulary? What tier? Do I need prior authorization?” Prior authorization (PA) requirements are the most common barrier to access, even when you technically qualify.

How to Apply: Step-by-Step Guide to Accessing GLP-1 Through Medicare

1. Get your medical documentation in order. Your prescriber will need documented evidence of your qualifying condition—cardiovascular disease diagnosis, Type 2 diabetes records, BMI measurements, and any weight-related comorbidities. Request copies of relevant records before your appointment.
2. Schedule a dedicated medication review appointment. Don’t try to add a GLP-1 prescription request to a routine visit. Book a dedicated appointment to discuss GLP-1 eligibility with your primary care physician or cardiologist. Come prepared with your eligibility documentation.
3. Ask your doctor to check prior authorization requirements. Most GLP-1 prescriptions for Medicare patients require prior authorization. Your doctor’s office will need to submit clinical documentation to your plan. This process can take 1–2 weeks.
4. Confirm your Part D formulary tier. Even if approved, your cost-sharing will depend on which tier the drug is placed on. Ask your plan specifically: what is my copay or coinsurance for this drug at my preferred pharmacy?
5. If standard Part D doesn’t cover it, explore the TrumpRx portal or pilot programs. Ask your prescriber about direct-access programs if your plan’s formulary cost-sharing is prohibitive.
6. File an appeal if denied. If your prior authorization is denied, you have the right to appeal. Your doctor can submit a medical necessity letter. Coverage denials for Wegovy in cardiovascular patients have been successfully overturned on appeal when proper documentation is submitted.

What You’ll Pay: Cost Comparison by Access Pathway

Costs are estimates based on 2026 data and vary by pharmacy, plan, and geographic market. The $2,100 Part D annual out-of-pocket cap applies to GLP-1 costs under Part D coverage.

What Seniors Should Know About GLP-1 Side Effects

GLP-1 medications carry specific considerations for adults over 65 that are important to discuss with your doctor before starting:

• Muscle mass loss: Rapid weight loss at any age can reduce muscle mass. Seniors are advised to combine GLP-1 therapy with resistance training and adequate protein intake to preserve muscle during weight loss.
• Gastrointestinal side effects: Nausea, vomiting, and diarrhea are common, especially early in treatment. Starting at the lowest dose and titrating slowly is recommended.
• Malnutrition risk: Reduced appetite can lead to inadequate nutrition in seniors. Regular monitoring of nutritional status is recommended.
• Drug interactions: GLP-1 medications slow gastric emptying, which can affect the absorption timing of other oral medications. Review all current medications with your prescriber.
• Bone density: Rapid weight loss can affect bone density. Seniors already at risk for osteoporosis should discuss this with their doctor.

Frequently Asked Questions

Does Medicare cover Wegovy for weight loss in 2026?

Medicare Part D can cover Wegovy (semaglutide 2.4mg) in 2026 when it is prescribed for cardiovascular risk reduction in patients with established cardiovascular disease — not for weight loss as a standalone indication. If you do not have cardiovascular disease, you may still be able to access Wegovy through the TrumpRx direct-access program, certain Medicare Advantage supplemental benefits, or CMS pilot programs. Standard Medicare Part D cannot cover GLP-1 medications prescribed solely for weight loss under current federal law.

How do I qualify for the $50/month GLP-1 program through Medicare?

The $50/month access point for GLP-1 medications has been available through TrumpRx direct pharmacy portals and related programs. Qualifying generally requires enrollment in Medicare, a BMI of 30 or above (or 27+ with a qualifying weight-related condition), a prescription from a licensed provider, and verification through the program’s designated portal. Eligibility requirements and program availability can change—verify current terms and enrollment status directly through the official program before scheduling a prescription visit.

Does Medicare cover Zepbound (tirzepatide) for weight loss?

Medicare coverage for Zepbound (tirzepatide) for weight management specifically is limited under standard Part D. However, Mounjaro—the same active ingredient (tirzepatide) in a lower-dose formulation—is covered by Medicare Part D when prescribed for Type 2 diabetes. Access to Zepbound for weight management may also be available through select Medicare Advantage supplemental benefits, the TrumpRx program, or direct-pricing pharmacy portals, depending on your eligibility and your plan’s formulary.

What BMI do you need to qualify for Medicare GLP-1 coverage?

For GLP-1 medications approved for weight management (Wegovy, Zepbound), FDA approval requires a BMI of 30 or above OR a BMI of 27 or above with at least one weight-related comorbidity such as Type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnea, or cardiovascular disease. Medicare’s own coverage rules layer additional requirements on top of these FDA thresholds, depending on the specific access pathway being used.

Can Medicare deny coverage for a GLP-1 medication even if my doctor prescribes it?

Yes. A prescription from your doctor does not guarantee coverage. Medicare Part D plans can and do require prior authorization for GLP-1 medications, and they can deny coverage if the clinical documentation doesn’t meet the plan’s specific criteria for the indicated use. If your prior authorization is denied, you have the right to file an appeal. A detailed medical necessity letter from your prescriber documenting your qualifying condition significantly improves the likelihood of a successful appeal.